• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Pluri Inc.

    9/17/25 4:56:56 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PLUR alert in real time by email
    S-8 1 ea025734602-s8_pluriinc.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on September 17, 2025

     

    Registration No. 333-      

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933  

     

    PLURI INC.

    (Exact name of registrant as specified in its charter)

     

    Nevada   98-0351734
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)

     

    MATAM Advanced Technology Park,
    Building No. 5, Haifa, Israel
      3508409
    (Address of Principal Executive Offices)   (Zip Code)

     

    Pluri Inc. 2019 Equity Compensation Plan

    (Full title of the plan)

     

    Nevada Agency and Transfer Company

    50 West Liberty Street, Suite 880

    Reno, NV 89501

    (Name and address of agent for service)

     

    (775) 322-0626

    (Telephone number, including area code, of agent for service)

     

    Copy to:

     

    Oded Har-Even

    Howard E. Berkenblit

    Ron Ben-Bassat

    Sullivan & Worcester LLP

    1251 Avenue of the Americas

    New York, NY 10020

    Tel: (212) 660-3000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated non-accelerated filer, smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
      Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

    EXPLANATORY NOTE

     

    On September 9, 2020, Pluri Inc., or the Company, filed a Registration Statement on Form S-8 (File No. 333- 248685), or the Original Registration Statement, with the Securities and Exchange Commission, or the Commission, to register an aggregate of 584,375 common shares of the Company, or the Common Shares, that may be issued pursuant to the Company’s 2019 Equity Compensation Plan, or the 2019 Plan.

     

    On February 13, 2023, the Company filed a Registration Statement on Form S-8 (File No. 333-269736), or the Second Registration Statement, with the Commission to register an additional 437,500 Common Shares that may be issued pursuant to the 2019 Plan.

     

    On May 9, 2024, the Company filed a Registration Statement on Form S-8 (File No. 333-279255), or the Third Registration Statement, with the Commission to register an additional 100,000 Common Shares that may be issued pursuant to the 2019 Plan.

     

    Pursuant to the 2019 Plan, the number of Common Shares of the Company made available under the 2019 Plan shall not exceed 16% of the number of Common Shares issued and outstanding immediately on a fully diluted basis, as determined in accordance with the 2019 Plan, prior to the grant of awards.

     

    The Company is filing this Registration Statement on Form S-8 to register an additional 650,000 Common Shares, which may be issued in connection with securities awards which may hereafter be granted under the 2019 Plan.

     

    Pursuant to General Instruction E to Form S-8, the contents of the Original Registration Statement, the Second Registration Statement, and the Third Registration Statement, or collectively, the Prior Registration Statements, are incorporated herein by reference, except for Item 3 and Item 8 of Part II of the Prior Registration Statements, which are being updated by this registration statement.

     

     

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference. 

     

    The following additional documents, which have been filed by Pluri Inc., or the Company, with the Commission under the Securities Exchange Act of 1934, as amended, or the Exchange Act, are incorporated by reference in and made a part of this registration statement, as of their respective dates:

     

    (a) the Company’s Annual Report on Form 10-K for the year ended June 30, 2025, as filed with the Commission on September 17, 2025;

      

    (b) the Company’s Current Reports on Form 8-K filed with the Commission on July 3, 2025, September 11, 2025 and September 12, 2025; and

     

    (c) the description of the Company’s Common Shares contained in the Registration Statement on Form 8-A filed with the Commission on December 10, 2007, under the Exchange Act, as amended by Exhibit 4.1 to the Company’s Annual Report on Form 10-K for the year ended June 30, 2024, and including any further amendment or report filed or to be filed for the purpose of updating such description.

     

    In addition to the foregoing, all documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act subsequently filed by the Company prior to the filing of a post-effective amendment which indicates that all securities offered hereunder have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such documents and reports.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement herein, or in any subsequently filed document which also is or is deemed to be incorporated by reference, modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 8. Exhibits. 

     

    Exhibit No.   Description
    4.1   Composite Copy of the Company’s Articles of Incorporation, as amended on March 27, 2024 (incorporated by reference to Exhibit 3.3 of the Company’s quarterly report on Form 10-Q filed on May 9, 2024).
    4.2   Amended and Restated By-laws as amended on September 10, 2020 (incorporated by reference to Exhibit 3.3 of our annual report on Form 10-K filed on September 10, 2020).
    5.1*   Opinion of Sullivan & Worcester LLP.
    23.1*   Consent of Sullivan & Worcester LLP (contained in the opinion of Sullivan & Worcester LLP filed herewith as Exhibit 5.1).
    23.2*   Consent of Kesselman & Kesselman, Independent Registered Public Accounting Firm.
    24.1*   Powers of Attorney (included in the signature page to this registration statement).
    99.1   The Company’s 2019 Equity Compensation Plan (incorporated by reference from the Company’s definitive proxy statement on Schedule 14A filed with the Commission on April 25, 2019).
    107*   Filing fee table

     

    *   Filed herewith.

     

    II-1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Haifa, Israel, on September 17, 2025.

     

      PLURI INC.
         
      By: /s/ Yaky Yanay
        Yaky Yanay
        Chief Executive Officer

     

    POWER OF ATTORNEY AND SIGNATURES

     

    We, the undersigned officers and directors of Pluri Inc., hereby constitute and appoint Yaky Yanay and Liat Zaltz and each of them singly, our true and lawful attorneys-in-fact, with full power to them in any and all capacities, to sign any and all amendments to this registration statement on Form S-8 (including any post-effective amendments thereto), and to file the same, with exhibits thereto and other documents in connection therewith, with the Commission, hereby ratifying and confirming all that each of said attorneys-in-fact may do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Yaky Yanay   Chief Executive Officer, President and Director   September 17, 2025
    Yaky Yanay   (Principal Executive Officer)    
             
    /s/ Liat Zaltz   Chief Financial Officer and Treasurer   September 17, 2025
    Liat Zaltz   (Principal Financial and Accounting Officer)    
             
    /s/ Zami Aberman   Chairman of the Board of Directors   September 17, 2025
    Zami Aberman        
             
    /s/ Rami Levi   Director   September 17, 2025
    Rami Levi        
             
    /s/ Maital Shemesh-Rasmussen   Director   September 17, 2025
    Maital Shemesh-Rasmussen        
             
    /s/ Alexandre Weinstein   Director   September 17, 2025
    Alexandre Weinstein        
             
    /s/ Eitan Ajchenbaum   Director   September 17, 2025
    Eitan Ajchenbaum        
             

     

    II-2

    Get the next $PLUR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PLUR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PLUR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials

    NEW YORK, May 27, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it has signed a Letter of Intent (LOI) with Minaris Advanced Therapies, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, to manufacture NurOwn® for its upcoming clinical trial. The LOI marks the beginning of a strategic collaboration between BrainStorm and Minaris to initiate the technology transfer of NurOwn® in preparation for clinical trial manufacturing at Minaris' state-of-the-art facility in Allendale, New Jersey. This partnership supports

    5/27/25 7:00:00 AM ET
    $BCLI
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market Expansion

    Major milestones include entry into cultivated cacao and coffee markets and progress toward commercial-scale productionCompany reports nearly 400% revenue growth in the first nine months of fiscal year 2025 compared to the same period in fiscal year 2024, driven by its CDMO and AgTech businesses, and is advancing new food tech partnerships and licensing opportunities HAIFA, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq, TASE: PLUR) ("Pluri" or the "Company"), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today issued the following shareholder update from Chief Executive Officer an

    5/15/25 7:00:00 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DarioHealth Announces CFO Transition

    NEW YORK, April 21, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leading global digital health company, today announced that Zvi Ben-David, Chief Financial Officer, will retire from his role, effective May 15, 2025. The Company has appointed Chen Franco-Yehuda as its new Chief Financial Officer, Treasurer, and Secretary, and will assume the role upon Mr. Ben-David's retirement on May 15, 2025. To ensure a smooth transition, Mr. Ben-David will remain with the Company until the end of June, after which he will move to assist the Company in an advisory capacity. "It has been an incredible journey at DarioHealth, and I am proud of what we have accomplished,

    4/21/25 8:30:00 AM ET
    $BNRG
    $DRIO
    $PLUR
    Building Products
    Industrials
    Medical/Dental Instruments
    Health Care

    $PLUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manieu Alexandre Weinstein bought $4,500,001 worth of shares (976,139 units at $4.61) and disposed of 976,139 shares (SEC Form 4)

    4 - Pluri Inc. (0001158780) (Issuer)

    7/1/25 4:00:11 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PLUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manieu Alexandre Weinstein bought $4,500,001 worth of shares (976,139 units at $4.61) and disposed of 976,139 shares (SEC Form 4)

    4 - Pluri Inc. (0001158780) (Issuer)

    7/1/25 4:00:11 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Shemesh-Rasmussen Maital was granted 11,173 shares, increasing direct ownership by 154% to 18,445 units (SEC Form 4)

    4 - Pluri Inc. (0001158780) (Issuer)

    2/27/25 4:00:19 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Levi Rami Avraham was granted 11,173 shares, increasing direct ownership by 156% to 18,314 units (SEC Form 4)

    4 - Pluri Inc. (0001158780) (Issuer)

    2/27/25 4:00:22 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PLUR
    SEC Filings

    View All

    SEC Form S-3 filed by Pluri Inc.

    S-3 - Pluri Inc. (0001158780) (Filer)

    9/17/25 5:27:34 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Pluri Inc.

    S-8 - Pluri Inc. (0001158780) (Filer)

    9/17/25 4:56:56 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Pluri Inc.

    S-8 - Pluri Inc. (0001158780) (Filer)

    9/17/25 4:54:28 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PLUR
    Financials

    Live finance-specific insights

    View All

    BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

    Memorandum of Understanding has been signed NEW YORK, Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding (MOU) with Pluri Inc. (NASDAQ:PLUR) through its wholly owned subsidiary ("Pluri"), an established global leader in the development and manufacturing of cell-based therapeutics, to manufacture NurOwn® for use in BrainStorm's planned Phase 3b trial in amyotrophic lateral sclerosis (ALS). This MOU enables BrainStorm to begin transfer of its manufacturing technology and start producing NurOwn at Pluri's manufacturing facil

    11/11/24 6:00:00 AM ET
    $BCLI
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PLUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Pluri Inc. (Amendment)

    SC 13G/A - Pluri Inc. (0001158780) (Subject)

    2/13/24 4:34:49 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Pluri Inc. (Amendment)

    SC 13G/A - Pluri Inc. (0001158780) (Subject)

    2/1/24 4:02:29 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Pluri Inc. (Amendment)

    SC 13G/A - Pluri Inc. (0001158780) (Subject)

    9/15/23 4:00:03 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PLUR
    Leadership Updates

    Live Leadership Updates

    View All

    Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

    HAIFA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotech company that transforms cells into solutions that promote global wellbeing and sustainability, today announced the appointment of attorney James Roosevelt, Jr. to the Company's Advisory Board. Having served in public-service positions in Washington, D.C., followed by a successful decade in the private sector as CEO of Tufts Health Plan, Mr. Roosevelt is a trusted and sought-after advisor on business matters, legislative and regulatory issues, governance, and personnel matters. The intersection of public policy and health is a passion for him. As CEO of

    3/6/24 7:00:00 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors

    HAIFA, Israel, July 13, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotech company that transforms cells into solutions that promote wellbeing and sustainability, today announced the appointment of Lorne Abony to the Company's Board of Directors, effective as of July 11, 2023.  Abony is a successful entrepreneur who has decades of experience building and scaling multi-billion-dollar global businesses – both public and private companies – across multiple industries. He is a globally recognized leader who has invested, directly or indirectly, in more than 20 cellular agriculture and cultivated food companies. Bringing his expertise t

    7/13/23 2:00:00 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care